Php287 - German Early Benefit Assessments of Orphan Drugs Under Full Dossier Conditions

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1181
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Iqwig Early Benefit Assessments of Type 2 Diabetes Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Php325 - Orphan Drugs‘ Market Access Challenges in Europe From a German Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Inclusion and Consideration of Patient Preferences in Amnog Early Benefit Assessments

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Pcn304 - Appropriate Comparator in German Amnog Benefit Assessments in Melanoma – A Dynamic Situation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn309 - Diversity in Safety Data Analyses in German Amnog Benefit Assessments for Multiple Myeloma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy60 - Orphan Versus Ultra-Orphan Drugs Prices in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pms83 - Comparison of French and German Hta Assessments for Three Recently Evaluated Rheumatoid Arthritis Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Identification of Approval Conditions for Orphan Drugs for Neurological Disorders by the Japanese Regulatory Agency

Expert Opinion on Orphan Drugs
ToxicologyPharmaceuticsPharmacologyHealth Policy
2018English

Mechanism of Coordinated Access to Orphan Drugs

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy